Market Overview:
The global retinal vascular occlusion market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of retinal vascular occlusions, rising awareness about available treatment options, and growing demand for minimally invasive procedures. Based on type, the global retinal vascular occlusion market is segmented into anti-vascular endothelial growth factor (VEGF), corticosteroid, anticoagulants, fibrinolytic agents, and others. The anti-VEGF segment is expected to account for the largest share of the global retinal vascular occlusion market in 2018. This segment is projected to grow at a CAGR of 8% during the forecast period from 2018 to 2030. The large share of this segment can be attributed to factors such as increasing prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME), rising adoption rates for anti-VEGF therapies among patients with AMD and DME, and growing demand for novel therapies that offer better outcomes than existing treatments options.
Product Definition:
Retinal vascular occlusion is a blockage of the blood vessels in the retina, which can lead to vision loss. It can be caused by a number of factors, including diabetes, high blood pressure, and atherosclerosis. Retinal vascular occlusion is a serious condition and requires prompt treatment.
Anti-vascular Endothelial Growth Factor (VEGF):
Anti-vascular endothelial growth factor (VEGF) is a protein that regulates the process of angiogenesis or the formation of new blood vessels. Angiogenesis is stimulated by various factors such as hypoxia, inflammation, and injury. VEGF has been known to be produced in response to these conditions and it helps in the growth of new blood vessels for healing purposes.
Corticosteroid:
Corticosteroid is a type of medication that reduces inflammation by inhibiting the action of cytokines. Cytokines are proteins that act as messengers between cells. The most commonly used corticosteroids are betamethasone, dexamethasone, fluorometholone, and methylprednisolone.
Application Insights:
Based on application, the market is segmented into hospitals and clinics, research and academia, others (private practice) and regional analysis based on North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Hospitals and clinics held the largest share in 2017 owing to a large number of retinal vascular occlusion cases being diagnosed at hospitals compared to other settings. In addition, hospital-based clinical trials are able to test new drugs for short-term use in patients with RVO due to better infrastructure supporting such trials.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to increasing prevalence of retinal vein occlusion, rising geriatric population, and high adoption of advanced treatment procedures. Moreover, growing number of research studies conducted on various treatments for RVO is further expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to factors such as improving healthcare infrastructure and growing target population base in this region. Furthermore, increasing medical tourism due to availability of advanced treatment options for RVO at lower costs will also boost regional growth over the next eight years time frame.
Key players operating in this industry include but are not limited with Abbott; Pfizer Inc.
Growth Factors:
- Increasing incidence of retinal vascular occlusion due to the growing prevalence of diabetes and hypertension.
- Rising geriatric population, who are more susceptible to developing retinal vascular occlusion.
- Growing demand for minimally invasive procedures for treating retinal vascular occlusions.
- Technological advancements in the field of ophthalmology that are helping in early diagnosis and treatment of retinal vascular occlusions
Scope Of The Report
Report Attributes
Report Details
Report Title
Retinal Vascular Occlusion Market Research Report
By Type
Anti-vascular Endothelial Growth Factor (VEGF), Corticosteroid, Anticoagulants, Fibrinolytic, Others
By Application
Hospitals and Clinics, Research and Academics, Others
By Companies
Regeneron Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals LLC., Novartis AG, Pfizer, Inc., AstraZeneca PLC., GlaxoSmithKline PLC., Johnson & Johnson, Teva pharmaceutical industries, Novo Nordisk, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Retinal Vascular Occlusion Market Report Segments:
The global Retinal Vascular Occlusion market is segmented on the basis of:
Types
Anti-vascular Endothelial Growth Factor (VEGF), Corticosteroid, Anticoagulants, Fibrinolytic, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Research and Academics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Regeneron Pharmaceuticals, Inc.
- Bayer HealthCare Pharmaceuticals LLC.
- Novartis AG
- Pfizer, Inc.
- AstraZeneca PLC.
- GlaxoSmithKline PLC.
- Johnson & Johnson
- Teva pharmaceutical industries
- Novo Nordisk
- Sanofi
Highlights of The Retinal Vascular Occlusion Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-vascular Endothelial Growth Factor (VEGF)
- Corticosteroid
- Anticoagulants
- Fibrinolytic
- Others
- By Application:
- Hospitals and Clinics
- Research and Academics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Retinal Vascular Occlusion Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Retinal vascular occlusion is a condition in which the blood flow to one or more of the retinal arteries is blocked. This can lead to blindness.
Some of the major players in the retinal vascular occlusion market are Regeneron Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals LLC., Novartis AG, Pfizer, Inc., AstraZeneca PLC., GlaxoSmithKline PLC., Johnson & Johnson, Teva pharmaceutical industries, Novo Nordisk, Sanofi.
The retinal vascular occlusion market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Retinal Vascular Occlusion Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Retinal Vascular Occlusion Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Retinal Vascular Occlusion Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Retinal Vascular Occlusion Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Retinal Vascular Occlusion Market Size & Forecast, 2018-2028
4.5.1 Retinal Vascular Occlusion Market Size and Y-o-Y Growth
4.5.2 Retinal Vascular Occlusion Market Absolute $ Opportunity
Chapter 5 Global Retinal Vascular Occlusion Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Retinal Vascular Occlusion Market Size Forecast by Type
5.2.1 Anti-vascular Endothelial Growth Factor (VEGF)
5.2.2 Corticosteroid
5.2.3 Anticoagulants
5.2.4 Fibrinolytic
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Retinal Vascular Occlusion Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Retinal Vascular Occlusion Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Research and Academics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Retinal Vascular Occlusion Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Retinal Vascular Occlusion Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Retinal Vascular Occlusion Analysis and Forecast
9.1 Introduction
9.2 North America Retinal Vascular Occlusion Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Retinal Vascular Occlusion Market Size Forecast by Type
9.6.1 Anti-vascular Endothelial Growth Factor (VEGF)
9.6.2 Corticosteroid
9.6.3 Anticoagulants
9.6.4 Fibrinolytic
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Retinal Vascular Occlusion Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Research and Academics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Retinal Vascular Occlusion Analysis and Forecast
10.1 Introduction
10.2 Europe Retinal Vascular Occlusion Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Retinal Vascular Occlusion Market Size Forecast by Type
10.6.1 Anti-vascular Endothelial Growth Factor (VEGF)
10.6.2 Corticosteroid
10.6.3 Anticoagulants
10.6.4 Fibrinolytic
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Retinal Vascular Occlusion Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Research and Academics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Retinal Vascular Occlusion Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Retinal Vascular Occlusion Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Retinal Vascular Occlusion Market Size Forecast by Type
11.6.1 Anti-vascular Endothelial Growth Factor (VEGF)
11.6.2 Corticosteroid
11.6.3 Anticoagulants
11.6.4 Fibrinolytic
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Retinal Vascular Occlusion Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Research and Academics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Retinal Vascular Occlusion Analysis and Forecast
12.1 Introduction
12.2 Latin America Retinal Vascular Occlusion Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Retinal Vascular Occlusion Market Size Forecast by Type
12.6.1 Anti-vascular Endothelial Growth Factor (VEGF)
12.6.2 Corticosteroid
12.6.3 Anticoagulants
12.6.4 Fibrinolytic
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Retinal Vascular Occlusion Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Research and Academics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Retinal Vascular Occlusion Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Retinal Vascular Occlusion Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Retinal Vascular Occlusion Market Size Forecast by Type
13.6.1 Anti-vascular Endothelial Growth Factor (VEGF)
13.6.2 Corticosteroid
13.6.3 Anticoagulants
13.6.4 Fibrinolytic
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Retinal Vascular Occlusion Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Research and Academics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Retinal Vascular Occlusion Market: Competitive Dashboard
14.2 Global Retinal Vascular Occlusion Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Regeneron Pharmaceuticals, Inc.
14.3.2 Bayer HealthCare Pharmaceuticals LLC.
14.3.3 Novartis AG
14.3.4 Pfizer, Inc.
14.3.5 AstraZeneca PLC.
14.3.6 GlaxoSmithKline PLC.
14.3.7 Johnson & Johnson
14.3.8 Teva pharmaceutical industries
14.3.9 Novo Nordisk
14.3.10 Sanofi
